Aardvark Therapeutics, Inc. Common Stock (AARD) Stock Price

AARDStock
$7.2529.58%52W
Market Cap$158.67M
P/E
PEG Ratio
Div yield
Beta3.84

AARD Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-56.86%
Price vs S&P 500 (4W)4.11%
VGM Score59.52

AARD Earnings Surprise History

Q2 25-0.66est. -0.60
Q3 25-0.75est. -0.82
Q4 25-0.81est. -0.83
Q1 26-0.99est. -0.91
Q2 26-0.66est. -0.88

AARD Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.11
3.89
3.78
3.78

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
AARDAardvark Therapeutics, Inc. Common Stock
C$7.25
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Aardvark Therapeutics, Inc. Common Stock

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics that target Bitter Taste Receptors (TAS2Rs) to treat metabolic and hunger-associated conditions. The company's lead candidate, ARD-101, is an oral gut-restricted TAS2R agonist currently in Phase 3 clinical trials for hyperphagia associated with Prader-Willi Syndrome.